Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASH 2019

7 - 10 Dec 2019
Orlando, Orlando, United States of America
Videos
News
Treating haematological cancers in Romania
Dr Ciprian Tomuleasa - Ion Chiricuta Clinical Research Center, Cluj Napoca...
Treating haematological cancers in Romania ( Dr Ciprian Tomuleasa - Ion Chiricuta Clinical Research Center, Cluj Napoca, Romania )
10 Mar 2020
The landscape of haematological cancers in India
Dr Hemant Malhotra - Mahatma Gandhi Medical College Hospital, Jaipur, India
The landscape of haematological cancers in India ( Dr Hemant Malhotra - Mahatma Gandhi Medical College Hospital, Jaipur, India )
10 Mar 2020
Haematological malignancies: Latest advances from ASH 2019
Dr Eloísa Riva - Hospital de Clínicas, Montevideo, Uruguay
Haematological malignancies: Latest advances from ASH 2019 ( Dr Eloísa Riva - Hospital de Clínicas, Montevideo, Uruguay )
10 Mar 2020
Cancer care in Argentina
Dr Maria Agustina Perusini - Hospital Italiano de Buenos Aires, Buenos Aires...
Cancer care in Argentina ( Dr Maria Agustina Perusini - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )
10 Mar 2020
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline...
Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML ( Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA )
27 Jan 2020
Are remissions for AML patients 'better' after daunorubicin and cytarabine...
Prof Daniel Ryan - University of Rochester, Rochester, USA
Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
17 Dec 2019
Predicting early relapse in transplant-eligible MM patients using baseline...
Dr Francesca Gay - University of Torino, Torino, Italy
Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Using multiparameter flow cytometry and next generation sequencing to evaluate...
Dr Francesca Gay - University of Torino, Torino, Italy
Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )
17 Dec 2019
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible...
Prof David Cairns - University of Leeds, Leeds, UK
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )
17 Dec 2019
Myeloma highlights from ASH 2019
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
FLT3-inhibition in infants with acute lymphoblastic leukaemia
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
13 Dec 2019
Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
13 Dec 2019
Benefits of apixaban among venous thromboembolism patients with active cancer
Dr Alexander Cohen - Guys and St Thomas, London, UK
Benefits of apixaban among venous thromboembolism patients with active cancer ( Dr Alexander Cohen - Guys and St Thomas, London, UK )
13 Dec 2019
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Dec 2019
Dasatinib vs imatinib for paediatric Ph ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
12 Dec 2019
Study of quadruple combination for induction resistant myeloma reveals novel...
Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )
12 Dec 2019
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
12 Dec 2019
Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Dec 2019
Eligibility criteria in acute myeloid leukaemia clinical trials
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Eligibility criteria in acute myeloid leukaemia clinical trials ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
12 Dec 2019
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia
Dr Robert Kreitman - National Cancer Institute, Bethesda, USA
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia ( Dr Robert Kreitman - National Cancer Institute, Bethesda, USA )
12 Dec 2019
Azacitidine plus nivolumab in older adults with AML or MDS
Prof Annette Hay - Queen's University, Ontario, Canada
Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )
12 Dec 2019
Venetoclax chemo combo active and well-tolerated in children with r/r AML
Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA
Venetoclax chemo combo active and well-tolerated in children with r/r AML ( Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA )
12 Dec 2019
Precision medicine treatment in older AML: Results of Beat AML master trial
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Precision medicine treatment in older AML: Results of Beat AML master trial ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
10 Dec 2019
Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T...
Dr Karl Kilgore - Avalere Health, Bowie, USA
Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapy ( Dr Karl Kilgore - Avalere Health, Bowie, USA )
10 Dec 2019
Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone...
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA
Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...
Prof Deepu Madduri - Mount Sinai, New York, USA
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )
10 Dec 2019
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Identifying prognostic constellations of driver mutations in acute myeloid...
Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA
Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes ( Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
CANDOR: Triple drug combo delays disease progression in stubborn multiple...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Maintenance therapy with CC-486 for acute myeloid leukaemia
Prof Andrew Wei - Monash University, Melbourne, Australia
Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Daratumuab, carfilzomib and dexamethasone increases survival in patients with...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome...
Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients...
Prof Andrew Wei - Monash University, Melbourne, Australia
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Blinatumomab demonstrates superior efficacy compared to chemotherapy in...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Multiple myeloma highlights from ASH 2019
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
10 Dec 2019
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed...
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2019
Glasdegib in combination with azacitidine in patients with untreated higher...
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
9 Dec 2019
Addressing the treatment gap for patients with relapsed/refractory primary...
Prof Evangelos Terpos and Prof Efstathios Kastritis
Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )
9 Dec 2019
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
9 Dec 2019
Challenges and importance of long-term treatment for newly diagnosed multiple...
Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin
Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )
9 Dec 2019
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell...
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )
9 Dec 2019
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise
Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )
8 Dec 2019
Evaluating emerging mutations in patients with acute myeloid leukaemia who...
Dr Catherine Smith - University of California San Francisco, San Francisco, USA
Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )
8 Dec 2019
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD...
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )
8 Dec 2019
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained...
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Dual-targeted antibody mosunetuzumab elicits durable responses in poor...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have...
Prof Deepu Madduri - Mount Sinai, New York, USA
Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate ( Prof Deepu Madduri - Mount Sinai, New York, USA )
7 Dec 2019
Cellular immunotherapy for B cell cancers shows promise
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
Cellular immunotherapy for B cell cancers shows promise ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )
7 Dec 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation